Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer

Src tyrosine kinases are overexpressed in pancreatic cancers, and the oral Src inhibitor saracatinib has shown antitumor activity in preclinical models of pancreas cancer. We performed a CTEP-sponsored Phase II clinical trial of saracatinib in previously treated pancreas cancer patients, with a prim...

Descripción completa

Detalles Bibliográficos
Autores principales: Arcaroli, John, Quackenbush, Kevin, Dasari, Arvind, Powell, Rebecca, McManus, Martine, Tan, Aik-Choon, Foster, Nathan R, Picus, Joel, Wright, John, Nallapareddy, Sujatha, Erlichman, Charles, Hidalgo, Manuel, Messersmith, Wells A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544442/
https://www.ncbi.nlm.nih.gov/pubmed/23342270
http://dx.doi.org/10.1002/cam4.27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544442/
https://www.ncbi.nlm.nih.gov/pubmed/23342270
http://dx.doi.org/10.1002/cam4.27

Ejemplares similares